Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Dec;133(12):3247-3255.
doi: 10.1002/lary.30706. Epub 2023 Apr 17.

Ipratropium Bromide Nasal Spray in Non-Allergic Rhinitis: A Systematic Review and Meta-Analysis

Patrick El Khoury  1 , Walid Abou Hamad  1 , Michel G Khalaf  1 , Christopher El Hadi  1 , Ralph Assily  1 , Simon Rassi  1 , Nadim Khoueir  1
Affiliations
Meta-Analysis

Ipratropium Bromide Nasal Spray in Non-Allergic Rhinitis: A Systematic Review and Meta-Analysis

Patrick El Khoury et al. Laryngoscope. 2023 Dec.

Abstract

Objective: This study aims to compare the effectiveness of intranasal ipratropium bromide (INIB) to a placebo in reducing nasal symptoms, particularly rhinorrhea, and enhancing quality of life in non-allergic rhinitis (NAR) patients.

Study design: Systematic review and meta-analysis.

Methods: A comprehensive review of the literature was conducted on Medline, Embase, and Cochrane libraries. Randomized controlled trials (RCTs) and non-randomized comparative parallel group trials comparing IB nasal spray to placebo were included.

Results: Five RCTs assessed a total of 472 participants with a diagnosis of NAR. IB nasal spray 0.03% were used across all studies. IB has a better impact on decreasing rhinorrhea than the placebo, with a standardized mean difference (SMD) of 0.93 (95% CI 0.06-1.8). The mean change in rhinorrhea severity was 85% (95% CI 77-92%) and I^2 26% (p = 0.24). IB outperformed the placebo in terms of shortening the symptom's duration/day, as shown by an SMD of 0.35 (95% CI 0.15-0.55). The difference between treatments was noticeable within the first week and remained consistent throughout the treatment. Patients who were administered IB experienced a substantially greater improvement in physical and mental outcomes. Nasal adverse events with IB were generally intermittent and brief.

Conclusion: Compared with a placebo, IB nasal spray is both safe and effective in treating the rhinorrhea associated with NAR. IB significantly reduces the severity and duration of rhinorrhea. The treatment was determined to be beneficial by both patients and physicians and resulted in a better quality of life.

Level of evidence: 1 Laryngoscope, 133:3247-3255, 2023.

Keywords: ipratropium bromide; nasal spray; nonallergic rhinitis; treatment.

PubMed Disclaimer

References

BIBLIOGRAPHY

    1. Kaliner MA. Classification of nonallergic rhinitis syndromes with a focus on vasomotor rhinitis, proposed to be known henceforth as nonallergic Rhinopathy. World Allergy Organ J. 2009;2(6):98-101.
    1. Pattanaik D, Lieberman P. Vasomotor rhinitis. Vol. 10, Current Allergy and Asthma Reports. Curr Allergy Asthma Rep. p. 84-91. 2010.
    1. Hellings PW, Klimek L, Cingi C, et al. Non-allergic rhinitis: position paper of the European academy of allergy and clinical immunology. Allergy. 2017;72(11):1657-1665.
    1. Varricchio A, Capasso M, De Lucia A, et al. Intranasal flunisolide treatment in patients with non-allergic rhinitis. Int J Immunopathol Pharmacol. 2011;24(2):401-409.
    1. Schroer B, Pien LC. Nonallergic rhinitis: common problem, chronic symptoms. Cleve Clin J Med. 2012;79(4):285-293.

LinkOut - more resources